Brief: EMA's CHMP Recommends Against Sanofi's Rezurock

Insmed

17/10/2025 11:28

Oct 17 (Reuters) - EMA's CHMP:

EMA'S CHMP: ADOPTED POSITIVE OPINION FOR WAYRILZ FOR TREATMENT OF IMMUNE THROMBOCYTOPENIA IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS

EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR BRINSUPRI

EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR REZUROCK FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

EMA'S CHMP: WITHDRAWS INITIAL MARKETING APPLICATION FOR HYDROCORTISONE AGUETTANT

EMA'S CHMP: ADOPTED NEW SUBCUTANEOUS ROUTE OF ADMINISTRATION FOR SAPHNELO, AN ADD-ON TREATMENT IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

EMA'S CHMP:  CONFIRMED ITS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE

EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR BREYANZI

EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR TREMFYA

EMA'S CHMP: CONFIRMS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE AS NEW ACTIVE SUBSTANCE

EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR PAXLOVID

 ((Reuters.Briefs@thomsonreuters.com;))